What Do Analysts Think About Amgen Inc. (AMGN)?

Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues.

In a report released on September 5, Vamil Divan from Guggenheim maintained a Hold rating on Amgen Inc. (NASDAQ:AMGN), setting a price target of $288.00.

However, Raymond James assumed coverage of the stock on September 3 with a Market Perform rating without assigning a price target.

The firm told investors that a meaningful extent of Amgen Inc.’s (NASDAQ:AMGN) valuation is for MariTide, whose clinical profile warrants its place as more of a niche player in the obesity market.

Amgen Inc.’s (NASDAQ:AMGN) analyst consensus is a Moderate Buy, with its median price target of $276.39 implying an upside of 12.16% from current levels.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.